Iovance Biotherapeutics (NASDAQ: IOVA) is going to finish the week strong on the stock market if its Thursday performance is any indication. Investors boosted the company's share price by almost 8 ...

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Iovance Biotherapeutics. The Motley Fool has a disclosure policy.

UBS analyst David Dai initiated coverage of Iovance Biotherapeutics (IOVA) with a Buy rating and $17 price target The firm launched coverage of SMID cap biotech sector with a focus in oncology and ...

About Interius BioTherapeutics Interius BioTherapeutics is a clinical stage biotechnology company engineering targeted, programmable vectors for the precision delivery of genetic medicines to ...

Interius BioTherapeutics is a clinical stage biotechnology company engineering targeted, programmable vectors for the precision delivery of genetic medicines to treat an array of challenging diseases ...

As of October 22, 2024, the average one-year price target for Iovance Biotherapeutics is 25.71 GBX/share. The forecasts range from a low of 10.39 GBX to a high of 36.73 GBX. The average price ...

Calidi Biotherapeutics ( (CLDI)) has shared an announcement. Calidi Biotherapeutics, a biotechnology company specializing in targeted antitumor therapies, has been notified by the NYSE that its ...